Mr. Speaker, first of all, I really enjoyed my colleague's presentation.
However—I hope she will agree with the Bloc Québécois—it is important for us that this bill be sent to committee so that we can call in as many experts as possible to fully explore this. I know that the member has experience in the health field, and so I would like to ask her a question.
Just replacing “drugs” by “therapeutic products” and adding to the terms “therapeutic products”, “drugs, devices, cells, tissues, organs” and so on, will probably result in a debate.
Is the member comfortable with the proposed definition for “therapeutic products”, or does it warrant a debate in committee?